MapLight is working to develop targeted, novel therapeutics to improve the lives of people with difficult-to-treat brain disorders. MapLight's unique discovery platform combines novel, proprietary technologies to uncover the individual circuits that misfire in brain disorders and target those circuits with effective, safe therapeutics. MapLight was founded in 2019 by a team of renowned neuroscientists who led the discovery of such groundbreaking technologies as optogenetics and STARmap.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/30/23 | $225,000,000 | Series C |
5AM Ventures Cowen Healthcare Investments Novo Holdings  | undisclosed |
